Archives
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
br Materials and methods br Results br
2025-02-11

Materials and methods Results Discussion Many studies investigate the role of 12/15-LOX in cancer cell,23, 24, 25 however we here first found that host 12/15-LOX also plays an important role in metastasis progression. We have demonstrated that 12(S)-HETE increased melanoma cell adhesion to
-
The importance of the ATM Tel to ATR Mec switch
2025-02-11

The importance of the ATM/Tel1 to ATR/Mec1 switch in the response to DSBs remains to be determined. Noteworthy, resection-defective S. cerevisiae cells, such as sae2Δ, exo1Δ, fun30Δ or sgs1Δ mutants, fail to turn off the checkpoint in response to an unrepaired DSB [56], [127], [128]. Moreover, the s
-
Another contributor for the G
2025-02-11

Another contributor for the G2/M arrest in A549 and H1299 cells might be p21WAF1/CIP1 which was up-regulated upon ovatodiolide treatment. p21WAF1/CIP1 is a common CDKs inhibitor which blocks mitotic inhibitors G2/M phase progression in various types of cancer cells (Kim et al., 2015, Liberio et al.
-
A high throughput screening campaign led to the
2025-02-11

A high-throughput screening campaign led to the discovery of the first series of both potent and selective ATR kinase inhibitors by Vertex Pharmaceuticals (Charrier et al., 2011). One of these compounds, VE-821, was shown to be a potent ATP-competitive inhibitor of ATR with minimal cross-reactivity
-
In addition understanding the relationship
2025-02-11

In addition, understanding the relationship between human metabolic processes and dietary antioxidant intake would provide opportunities for altering the diet to improve health (Prior, 2015). Prior et al. (2007) emphasized that excess reactive oxygen species, which occurred during the metabolism of
-
The current antifungal pipeline contains several categories
2025-02-11

The current antifungal pipeline contains several categories of compounds at different stages of development [1], [9], [10], [96]. In Table 1 we summarize the most promising antifungal molecules that are in preclinical and in clinical development. Several compounds in the pipeline are derivatives of
-
It has been proposed that angiotensin II Ang II
2025-02-11

It has been proposed that angiotensin II (Ang II) may upregulate COX-2 expression and the subsequent vasoconstrictor prostanoids production through the activation of AT-1 receptors in vascular smooth muscle cells (Hu et al., 2002). Additionally, this peptide is also able to stimulate the generation
-
Interestingly we found that co treatment with losartan preve
2025-02-11

Interestingly, we found that co-treatment with losartan prevented the increased participation of ROS from NADPH oxidase on the contractile response to Phe observed in Hg-treated rats. Moreover, losartan also prevented the reduction in the endothelial NO modulation of this response found in treated a
-
br Material and methods br Results br
2025-02-11

Material and methods Results Discussion In order to find new and improved ways of treating type 2 diabetes (T2D) and other related conditions it is vital that investigators gain a more in-depth understanding of the effects that anti-diabetic treatments, such as TZDs, have on molecules impli
-
br Author contributions br Financial disclosures br Acknowle
2025-02-11

Author contributions Financial disclosures Acknowledgements We thank Ms. Eva So for the editorial assistance. This work was supported by grants from the National Natural Science Foundation of China (No. 81622015, 81571042 and 81501143) and the National Basic Research Program of China (No. 2
-
Most of the identified aldose reductase inhibitors possess
2025-02-11

Most of the identified aldose reductase inhibitors possess undesirable effects like poor pharmacokinetic properties, hypersensitivity and Steven-Johnson Syndrome [1]. However, the main side effect is the lack of selectivity relative to aldehyde reductase (ALR1, EC 1.1.1.2). ALR1 plays the important
-
br Conclusion br Acknowledgement This work
2025-02-10

Conclusion Acknowledgement This work was supported by JSPS KAKENHI (Grant Number 15K18770). Introduction Neural crest KU0059436 are multipotent progenitors in the vertebrate embryo that give rise to a vast array of different cell types including pigment cells, craniofacial skeleton and mes
-
Growing evidence indicates that GRKs can exert
2025-02-10

Growing evidence indicates that GRKs can exert different effects within the cell depending on the stimulus, cell type, and localization [97], [121]. In this sense, we were the first to demonstrate a mitochondrial localization for GRK2 [122], later confirmed by other investigators [123], establishing
-
Notably our preliminary results confirmed that fluoxetine SS
2025-02-10

Notably, our preliminary results confirmed that fluoxetine (SSRIs, 5–10 mg/kg) and duloxetine (SNRIs, 5–10 mg/kg) could not enhance memory function in the novel object recognition or step-down passive avoidance tasks (data not shown). In the present study, we also found that vilazodone showed had no
-
br Materials and methods br Results br Discussion This
2025-02-10

Materials and methods Results Discussion This study demonstrates that treatment with a selective adenosine kinase inhibitor ABT-702, thereby enhancing extracellular adenosine, can provide partial protection from age-related hearing loss in C57BL/6J mice. Chronic treatment with ABT-702, comm
15682 records 16/1046 page Previous Next First page 上5页 1617181920 下5页 Last page